GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Neptunus Interlong Bio-Technique Co Ltd (HKSE:08329) » Definitions » Equity-to-Asset

Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Equity-to-Asset : 0.66 (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Shenzhen Neptunus Interlong Bio-Technique Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Shenzhen Neptunus Interlong Bio-Technique Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$1,018 Mil. Shenzhen Neptunus Interlong Bio-Technique Co's Total Assets for the quarter that ended in Jun. 2024 was HK$1,534 Mil.

The historical rank and industry rank for Shenzhen Neptunus Interlong Bio-Technique Co's Equity-to-Asset or its related term are showing as below:

HKSE:08329' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48   Med: 0.64   Max: 0.72
Current: 0.66

During the past 13 years, the highest Equity to Asset Ratio of Shenzhen Neptunus Interlong Bio-Technique Co was 0.72. The lowest was 0.48. And the median was 0.64.

HKSE:08329's Equity-to-Asset is ranked better than
59.36% of 1036 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs HKSE:08329: 0.66

Shenzhen Neptunus Interlong Bio-Technique Co Equity-to-Asset Historical Data

The historical data trend for Shenzhen Neptunus Interlong Bio-Technique Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Neptunus Interlong Bio-Technique Co Equity-to-Asset Chart

Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.71 0.64 0.61 0.64

Shenzhen Neptunus Interlong Bio-Technique Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.64 - 0.64 0.66

Competitive Comparison of Shenzhen Neptunus Interlong Bio-Technique Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Neptunus Interlong Bio-Technique Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Neptunus Interlong Bio-Technique Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Shenzhen Neptunus Interlong Bio-Technique Co's Equity-to-Asset falls into.



Shenzhen Neptunus Interlong Bio-Technique Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Shenzhen Neptunus Interlong Bio-Technique Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=993.336/1548.404
=0.64

Shenzhen Neptunus Interlong Bio-Technique Co's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=1018.492/1534.079
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Neptunus Interlong Bio-Technique Co  (HKSE:08329) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Shenzhen Neptunus Interlong Bio-Technique Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Shenzhen Neptunus Interlong Bio-Technique Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Traded in Other Exchanges
N/A
Address
95 Queensway, 18th Floor, United Centre, Admiralty, Hong Kong, HKG
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sales of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines; and the Sales and distribution of medicines and healthcare products. The majority of revenue is generated from the Manufacturing and selling of medicines.

Shenzhen Neptunus Interlong Bio-Technique Co Headlines

No Headlines